Involvement of peripheral type of benzodiazepine receptor in social isolation stress-induced decrease in pentobarbital sleep in mice.
Our previous studies have shown that central-type benzodiazepine (BZD) receptors (CBR) and neurosteroids capable of modulating GABA(A) receptor function are involved in the decrease of pentobarbital (PB)-induced sleep caused by social isolation stress in mice. In this study, to further clarify the mechanism underlying this decrease, we investigated the possible involvement of peripheral-type BZD receptors (PBR) which play an important role in neurosteroidogenesis in PB sleep in socially isolated mice. Socially isolated mice showed significantly shorter duration of PB-induced sleep than group-housed animals. When injected intracerebroventricularly (i.c.v.), FGIN-1-27 (FGIN, 25-100 nmol), a selective PBR agonist, and PK11195 (PK, 14-28 nmol), a PBR antagonist, and pregnenolone (PREG, 15-30 nmol), a neurosteroid precursor, dose-dependently normalized the PB sleep in isolated mice without having an effect on the group-housed animals. In contrast, pregnenolone sulfate (PS, 24 nmol), an endogenous neurosteroidal negative allosteric modulator of the GABA(A) receptor, reduced PB sleep in group-housed but not isolated mice. PS, at the same dose, significantly attenuated the effects of FGIN (100 nmol), PK (28 nmol) and PREG (30 nmol) in isolated mice, while FGIN (100 nmol), PK (28 nmol) and pregnenolone (30 nmol) significantly blocked the effect of PS (24 nmol) in group-housed mice. These results suggest that the PBR-mediated decrease in the genesis of neurosteroid(s) possessing a GABA(A) receptor agonistic profile is also partly involved in the down regulation of the GABA(A) receptor following long-term social isolation and contributes to the decrease of PB-induced sleep in isolation stressed mice.
Dong
E
E
Department of Pharmacology, Research Institute for Wakan-Yaku (Oriental Medicines), Toyama Medical and Pharmaceutical University, Sugitani, Japan.
Matsumoto
K
K
Watanabe
H
H
D000818:Animals; D004305:Dose-Response Relationship, Drug; D018755:GABA Agonists / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D018757:GABA Modulators / Q000494:pharmacology*; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D007210:Indoleacetic Acids / Q000378:metabolism / Q000494:pharmacology; D007546:Isoquinolines / Q000378:metabolism / Q000494:pharmacology; D008297:Male; D051379:Mice; D010424:Pentobarbital / Q000494:pharmacology*; D011284:Pregnenolone / Q000378:metabolism / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000145:classification / Q000378:metabolism / Q000502:physiology*; D012890:Sleep / Q000187:drug effects / Q000502:physiology*; D012934:Social Isolation; D013312:Stress, Physiological / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology*
D018755:GABA Agonists; D018756:GABA Antagonists; D018757:GABA Modulators; D006993:Hypnotics and Sedatives; D007210:Indoleacetic Acids; D007546:Isoquinolines; D011963:Receptors, GABA-A; C081306:N,N-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide; D011284:Pregnenolone; D010424:Pentobarbital; C037850:PK 11195